|
See related Avelox information |
|
|
|
Manufacturer |
Bayer HealthCare Pharma |
|
Distributor |
DKSH |
|
Contents |
Moxifloxacin HCl |
|
Indications |
Treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia, acute sinusitis, uncomplicated skin & skin structure infections, uncomplicated pelvic inflammatory disease (ie female upper genital tract infections including salpingitis & endometritis), complicated skin & skin structure infections (including diabetic foot infections), complicated intraabdominal infections including polymicrobial infections eg abscesses.
Click to view Avelox detailed prescribing infomation |
|
Dosage |
Adult ≥18 yr 400 mg once daily. Duration of treatment: Acute exacerbation of chronic bronchitis 5 days. Community-acquired pneumonia 10 days. Acute sinusitis, uncomplicated skin & skin structure infections 7 days. Uncomplicated pelvic inflammatory disease 14 days. Complicated skin & skin structure infections total treatment duration for sequential therapy (IV followed by oral therapy) 7-21 days. Complicated intra-abdominal infections total treatment duration for sequential therapy (IV followed by oral therapy) 5-14 days.
Click to view Avelox detailed prescribing infomation |
|
Overdosage |
View Avelox overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow tab whole.). |
|
Contraindications |
Hypersensitivity to quinolones. Childn, growing adolescent. Pregnancy, lactation.
Click to view Avelox detailed prescribing infomation |
|
Special Precautions |
Patients w/ known QT interval prolongation or patients on concomitant medication known to prolong the QTc interval. Uncorrected hypokalemia; ongoing proarrhythmic conditions; seizures, known or suspected CNS disorders which may predispose to seizures or lower the seizure threshold; severe hepatic impairment. Patients on class IA/III antiarrhythmics. Tendon inflammation & rupture may occur. Avoid extensive UV exposure.
Click to view Avelox detailed prescribing infomation |
|
Adverse Drug Reactions |
Mycotic superinfections, headache, dizziness, QT prolongation, nausea, vomiting, GI & abdominal complaints, diarrhea, increase in transaminases, inj & infusion site reactions.
View ADR Monitoring Form |
|
Drug Interactions |
Antacids, minerals, multivit, antiretrovirals (eg didanosine), sucralfate.
View more drug interactions with Avelox |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Avelox storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Avelox description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Avelox mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Avelox film-coated tablet |
|
Avelox 400 mg x 5's |
 |
|
|
Avelox infusion |
|
Avelox 400 mg/250 mL x 1's |
 |
|
|
|
Manufacturer: |
Bayer HealthCare Pharma |
|
Distributor: |
DKSH
|
|
|
|
